Get Support – Call 1-888-MITO-411

LC-Fatty Acid Oxidation Disorders: Recent Updates on the REN001 Study

Print Friendly, PDF & Email

There was much discussion about current research in FAODs at the 2022 International Metabolic conference. Reneo Pharmaceuticals recently released positive results from the REN001 Phase1b LC-FAOD Study. 

Dr. Alex Dorenbaum, Chief Medical Officer at Reneo Pharmaceuticals will provide background about the Reneo LC-FAOD clinical study and answer questions.

About the Speaker

Alejandro “Alex” Dorenbaum, MD

Alejandro “Alex” Dorenbaum, MD

Alejandro (Alex) Dorenbaum, M.D., is the Chief Medical Officer of Reneo Pharmaceuticals. Previously, he was Chief Medical Officer at Allakos, where he achieved proof-of-concept in clinical trials for novel therapeutic antibodies targeting inflammatory cells. He also served as Chief Medical Officer at Lumena Pharmaceuticals until its acquisition by Shire Pharmaceuticals. Prior to that, Alex worked at Genentech, where he was responsible for the respiratory programs for asthma and cystic fibrosis, and at BioMarin Pharmaceutical, where he conducted the clinical development of Kuvan. He began his career at Chiron Corporation, gaining broad expertise in several areas of drug development including biologics, small molecules and vaccines.

Alex received his M.D. from the National Autonomous University in Mexico City. He completed his residency in pediatrics at University of Texas Health Science Center and held a fellowship in allergy and immunology at Baylor College of Medicine. He maintains an active academic position as Clinical Professor in Pediatrics at Stanford University School of Medicine, where he specializes in allergy and immunology.

Upcoming
Events

View All
View Calendar

Expert
Series

View All

Upcoming Presentations

View Calendar

Last Presentation

Expert Series: At the crossroad of mitochondrial disease and mitochondrial dysfunction
Presented July 25, 2023

P.O. Box 310
Novi, MI 48376
(888) 648-6228
info@mitoaction.org